Kellert Lars, Wollenweber Frank Arne, Thomalla Götz, Nolte Christian H, Fiehler Jens, Ringleb Peter Arthur, Dorn Franziska
Department of Neurology, University Hospital, Klinikum der Universität München, LMU, Munich, Germany.
Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany.
Eur Stroke J. 2017 Dec;2(4):356-360. doi: 10.1177/2396987317727229. Epub 2017 Aug 17.
In randomised clinical trials (RCTs), endovascular thrombectomy (ET) was combined with intravenous thrombolysis (IVT) in the vast majority of patients. We aimed to analyse how German stroke centres manage IVT in patients receiving ET in daily routine.
We performed an online survey among neurologists and neurointerventionalists that included all German University hospitals and a selection of German community hospitals known to perform ET. The survey consisted of 20 questions and was open for reply from 20 December 2016 to 9 January 2017.
Overall, there were 110 replies, 76% (84/110) from neurologists and 20% (22/110) from neurointerventionalists. The majority of participants (75/99, 76%) reported to continue IVT after start of ET. Nine participants (9%) reported to stop IVT as a standard of care before ET and another 15 (15%) reported to stop IVT on a case-by-case basis. Thrombolysis is given intra-arterially in individual cases in 39% (37/99) and as a standard of care in 3% (3/99). Intra-arterial Heparin is given additionally as a standard procedure in 25% (24/96) and in individual cases in 11% (11/96). IVT is omitted even without contraindications before ET in 5% (5/95) as standard procedure and in 14% (13/95) in individual cases.
We observed a wide heterogeneity with respect to the management of IVT in the context of ET. Evidence from RCTs is not implemented in a large number of cases.
These findings emphasise a requirement for further education and implementation of standards for the management of intravenous thrombolysis in endovascular treated stroke patients.
在随机临床试验(RCT)中,绝大多数患者接受了血管内血栓切除术(ET)联合静脉溶栓(IVT)治疗。我们旨在分析德国的卒中中心在日常医疗中如何管理接受ET治疗患者的IVT。
我们对神经科医生和神经介入医生进行了一项在线调查,调查对象包括德国所有大学医院以及部分已知开展ET治疗的德国社区医院。该调查包含20个问题,于2016年12月20日至2017年1月9日开放作答。
总体而言,共收到110份回复,其中76%(84/110)来自神经科医生,20%(22/110)来自神经介入医生。大多数参与者(75/99,76%)报告称在开始ET治疗后继续进行IVT。9名参与者(9%)报告称作为标准治疗在ET治疗前停止IVT,另有15名(15%)报告称根据具体情况停止IVT。39%(37/99)的个体病例采用动脉内溶栓,3%(3/99)作为标准治疗。25%(24/96)作为标准程序额外给予动脉内肝素,11%(11/96)的个体病例给予。5%(5/95)作为标准程序、14%(13/95)的个体病例即使在ET治疗前无禁忌证时也省略IVT。
我们观察到在ET治疗背景下IVT管理存在广泛的异质性。大量病例未采用RCT的证据。
这些发现强调了对血管内治疗的卒中患者进行静脉溶栓管理的继续教育和标准实施的必要性。